Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01166672 · ClinicalTrials.gov registry record
BCRL Prevention Pilot
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 20
- Enrollment target
NCT01166672: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01166672 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01166672 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to establish feasiblity of recruiting obese breast cancer survivors at the end of treatment, getting those survivors to lose weight and attend follow-up visits for 6 months.
Primary Outcome
The primary outcome will be the precent of participants who complete 6 month follow-up appointments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-10 |
What the finished NCT01166672 record still lists
NCT01166672 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01166672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01166672 about?
NCT01166672 is a clinical study titled "BCRL Prevention Pilot". The purpose of this study is to establish feasiblity of recruiting obese breast cancer survivors at the end of treatment, getting those survivors to lose weight and attend follow-up visits for 6 months.
What is the current status of trial NCT01166672?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2010-07. Estimated completion is 2012-10.
Who is sponsoring clinical trial NCT01166672?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia